Arctoris was featured in Fierce Biotech following a period of significant growth, highlighting the company’s expansion and the development of a strengthened executive leadership team.
The article reports that Arctoris co-founder Tom Fleming, Ph.D., has taken on the role of CEO, succeeding co-founder Martin-Immanuel Bittner, M.D., Ph.D., who led the company from 2018 to early 2024. The company also appointed Ian Shott as Chair of the Board, bringing extensive leadership experience from the life sciences sector.
The expanded executive team includes several key appointments designed to support the company’s continued growth:
Anthony Rowen-Brown, Ph.D. – Chief Scientific Officer
Kinga Bercsenyi, Ph.D. – Chief Business Officer
Paul Custance – Chief Financial Officer
Sally Cullen – Chief People Officer
Alice “Poppy” Roworth, Ph.D. – Chief Operating Officer
Fierce Biotech notes that Arctoris’ growth has been driven in part by increasing demand from pharmaceutical and biotechnology partners using computational and AI-driven approaches to drug discovery. These approaches generate large numbers of hypotheses that require rapid experimental validation.
Arctoris supports these programs through its Ulysses automated experimentation platform, which combines robotics, software, and scientific expertise to enable scalable drug discovery experimentation. The company operates internationally, with locations in Oxford, UK, and Boston, USA.